Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2 – Dosing initiated in Cohort 2 of the registrational study; topline single-ascending-dose data expected in the first half of 2027 –
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.